Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
Atezolizumab injection is used to treat urothelial carcinoma (a type of bladder cancer) that has spread throughout the body (metastatic) or cannot be removed by surgery (advanced). This medicine is given to patients who have received other cancer medicines (eg, platinum) that did not work well, or in patients who cannot receive cancer medicines containing cisplatin and whose cancer has high levels of a specific protein called programmed death-ligand 1 (PD-L1), or in patients with or without PD-L1- expressing cancers who cannot receive cancer medicines containing platinum.
Atezolizumab injection is used together with other cancer medicines (eg, bevacizumab, paclitaxel, and carboplatin combination, or paclitaxel protein-bound and carboplatin combination) as first-line treatment to metastatic non-squamous non-small cell lung cancer in patients whose tumor does not have an abnormal EGFR or ALK gene. It is also used to treat metastatic non-small cell lung cancer with or without an EGFR or ALK gene in patients who have received cancer medicines containing platinum that did not work well.
Atezolizumab injection is also used together with other cancer medicines (eg, paclitaxel protein-bound) to treat patients with triple-negative breast cancer (TNBC) that has spread or cannot be removed by surgery and whose tumors express PD-L1.
Atezolizumab injection is also used together with carboplatin and etoposide as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC).
This medicine is to be given only by or under the supervision of your doctor.
This product is available in the following dosage forms: